Dual antiplatelet versus alteplase in anterior and posterior circulation minor stroke
Objective The Antiplatelet versus R-tPA for Acute Mild Ischaemic Stroke trial has demonstrated the non-inferiority of dual antiplatelet therapy (DAPT) to alteplase in minor non-disabling stroke. This prespecified secondary analysis aimed to investigate whether the treatment effects were similar acro...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
|
| Series: | Stroke and Vascular Neurology |
| Online Access: | https://svn.bmj.com/content/early/2024/12/11/svn-2024-003705.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846118442459987968 |
|---|---|
| author | Yu Cui Hui-Sheng Chen |
| author_facet | Yu Cui Hui-Sheng Chen |
| author_sort | Yu Cui |
| collection | DOAJ |
| description | Objective The Antiplatelet versus R-tPA for Acute Mild Ischaemic Stroke trial has demonstrated the non-inferiority of dual antiplatelet therapy (DAPT) to alteplase in minor non-disabling stroke. This prespecified secondary analysis aimed to investigate whether the treatment effects were similar across stroke territories.Methods Participants were divided according to stroke territory, which were subdivided into DAPT and alteplase. An excellent functional outcome at 90 days defined as modified Rankin Scale scoring 0–1 was primary outcome. National Institutes of Health Stroke Scale (NIHSS) score change and early neurological improvement measured by a 2-point decline in NIHSS score at 24 hours were secondary outcomes. Symptomatic intracerebral haemorrhage (sICH) and bleeding events were safety outcomes. Primary analyses adjusted unbalanced baseline characteristics between treatments by multivariate logistic regression.Results A total of 719 patients were included: 566 in anterior circulation stroke (ACS) and 153 in posterior circulation stroke (PCS). Primary outcome was 94.1% in DAPT and 91.7% in alteplase among ACS patients (adjusted risk difference (RD) and 95% CI, 1.5% (−1.5% to 4.6%), p=0.32), while 91.2% in DAPT and 91.8% in alteplase among PCS patients (adjusted RD and 95% CI, −2.1% (−8.5% to 4.4%), p=0.53). Compared with alteplase, DAPT was associated with lower risk of sICH (p=0.03) and bleeding events (p<0.001) in ACS, but only lower risk of bleeding events (p=0.007) in PCS. Additionally, among ACS patients, the alteplase was superior to DAPT in terms of decrease in NIHSS score at 24 hours compared with admission (adjusted geometric mean ratio and 95% CI, −0.09 (−0.16 to −0.03), p=0.005) and early neurological improvement (adjusted RD and 95% CI, −7.2% (−11.6% to −2.7%), p=0.001).Conclusion Among ischaemic stroke with minor non-disabling symptoms, DAPT was similar with intravenous alteplase regarding long-term functional outcome and better safety regardless of ACS or PCS. The potential benefit of intravenous alteplase regarding early neurological improvement in patients with ACS warrants further investigation.Trial registration number NCT03661411. |
| format | Article |
| id | doaj-art-6fe9ed6e8bf649ba82aaf0caf52e76db |
| institution | Kabale University |
| issn | 2059-8696 |
| language | English |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Stroke and Vascular Neurology |
| spelling | doaj-art-6fe9ed6e8bf649ba82aaf0caf52e76db2024-12-17T18:50:13ZengBMJ Publishing GroupStroke and Vascular Neurology2059-869610.1136/svn-2024-003705Dual antiplatelet versus alteplase in anterior and posterior circulation minor strokeYu Cui0Hui-Sheng Chen1Department of Neurology, General Hospital of Northern Theatre Command, Shenyang, Liaoning, ChinaDepartment of Neurology, General Hospital of Northern Theatre Command, Shenyang, Liaoning, ChinaObjective The Antiplatelet versus R-tPA for Acute Mild Ischaemic Stroke trial has demonstrated the non-inferiority of dual antiplatelet therapy (DAPT) to alteplase in minor non-disabling stroke. This prespecified secondary analysis aimed to investigate whether the treatment effects were similar across stroke territories.Methods Participants were divided according to stroke territory, which were subdivided into DAPT and alteplase. An excellent functional outcome at 90 days defined as modified Rankin Scale scoring 0–1 was primary outcome. National Institutes of Health Stroke Scale (NIHSS) score change and early neurological improvement measured by a 2-point decline in NIHSS score at 24 hours were secondary outcomes. Symptomatic intracerebral haemorrhage (sICH) and bleeding events were safety outcomes. Primary analyses adjusted unbalanced baseline characteristics between treatments by multivariate logistic regression.Results A total of 719 patients were included: 566 in anterior circulation stroke (ACS) and 153 in posterior circulation stroke (PCS). Primary outcome was 94.1% in DAPT and 91.7% in alteplase among ACS patients (adjusted risk difference (RD) and 95% CI, 1.5% (−1.5% to 4.6%), p=0.32), while 91.2% in DAPT and 91.8% in alteplase among PCS patients (adjusted RD and 95% CI, −2.1% (−8.5% to 4.4%), p=0.53). Compared with alteplase, DAPT was associated with lower risk of sICH (p=0.03) and bleeding events (p<0.001) in ACS, but only lower risk of bleeding events (p=0.007) in PCS. Additionally, among ACS patients, the alteplase was superior to DAPT in terms of decrease in NIHSS score at 24 hours compared with admission (adjusted geometric mean ratio and 95% CI, −0.09 (−0.16 to −0.03), p=0.005) and early neurological improvement (adjusted RD and 95% CI, −7.2% (−11.6% to −2.7%), p=0.001).Conclusion Among ischaemic stroke with minor non-disabling symptoms, DAPT was similar with intravenous alteplase regarding long-term functional outcome and better safety regardless of ACS or PCS. The potential benefit of intravenous alteplase regarding early neurological improvement in patients with ACS warrants further investigation.Trial registration number NCT03661411.https://svn.bmj.com/content/early/2024/12/11/svn-2024-003705.full |
| spellingShingle | Yu Cui Hui-Sheng Chen Dual antiplatelet versus alteplase in anterior and posterior circulation minor stroke Stroke and Vascular Neurology |
| title | Dual antiplatelet versus alteplase in anterior and posterior circulation minor stroke |
| title_full | Dual antiplatelet versus alteplase in anterior and posterior circulation minor stroke |
| title_fullStr | Dual antiplatelet versus alteplase in anterior and posterior circulation minor stroke |
| title_full_unstemmed | Dual antiplatelet versus alteplase in anterior and posterior circulation minor stroke |
| title_short | Dual antiplatelet versus alteplase in anterior and posterior circulation minor stroke |
| title_sort | dual antiplatelet versus alteplase in anterior and posterior circulation minor stroke |
| url | https://svn.bmj.com/content/early/2024/12/11/svn-2024-003705.full |
| work_keys_str_mv | AT yucui dualantiplateletversusalteplaseinanteriorandposteriorcirculationminorstroke AT huishengchen dualantiplateletversusalteplaseinanteriorandposteriorcirculationminorstroke |